BioMarin Pharmaceutical Earnings: What To Look For From BMRN
Biotech company BioMarin Pharmaceutical is set to report earnings on Monday after market close. Last quarter, it met revenue expectations with $776.1 million, a 4.1% year-on-year increase, but missed EPS guidance. This quarter, revenue is expected to grow 11.6%, down from 15.6% last year. Analysts have maintained their estimates, despite BioMarin's history of missing revenue targets. In comparison, peers Biogen and Halozyme Therapeutics reported varied results. BioMarin's stock has risen 13.9% recently, with an average analyst price target of $88.87 against a current price of $64.08.
Biotech company BioMarin Pharmaceutical will be reporting results this Monday after market close. Here’s what to look for.
BioMarin Pharmaceutical met analysts’ revenue expectations last quarter, reporting revenues of $776.1 million, up 4.1% year on year. It was a softer quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and a significant miss of analysts’ EPS estimates.
Is BioMarin Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting BioMarin Pharmaceutical’s revenue to grow 11.6% year on year, slowing from the 15.6% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BioMarin Pharmaceutical has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at BioMarin Pharmaceutical’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 1.2%, beating analysts’ expectations by 3.6%, and Halozyme Therapeutics reported revenues up 51.6%, topping estimates by 0.6%. Biogen traded up 4.6% following the results while Halozyme Therapeutics was down 9%.
Read our full analysis of Biogen’s results here and Halozyme Therapeutics’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.2% on average over the last month. BioMarin Pharmaceutical is up 13.9% during the same time and is heading into earnings with an average analyst price target of $88.87 (compared to the current share price of $64.08).
